CHF Solutions, Inc. (CHFS): Price and Financial Metrics
GET POWR RATINGS... FREE!
CHFS Stock Price Chart Interactive Chart >
CHFS Price/Volume Stats
|Current price||$5.28||52-week high||$37.50|
|Prev. close||$5.22||52-week low||$4.86|
|Day high||$5.41||Avg. volume||467,323|
|50-day MA||$6.74||Dividend yield||N/A|
|200-day MA||$9.72||Market Cap||31.88M|
CHF Solutions, Inc. (CHFS) Company Bio
CHF Solutions, Inc., a medical device company, focuses on developing, manufacturing, and commercializing devices used in ultrafiltration therapy. The company's commercial product is the Aquadex FlexFlow System, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct Salesforce in the United States; and through independent specialty distributors primarily in the United Kingdom, Italy, Spain, Germany, Austria, Switzerland, Southeast Asia, Brazil, India, and Greece. The company was formerly known as Sunshine Heart, Inc. and changed its name to CHF Solutions, Inc. in May 2017. CHF Solutions, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Most Popular Stories View All
CHFS Latest News Stream
|Loading, please wait...|
CHFS Latest Social Stream
View Full CHFS Social Stream
Latest CHFS News From Around the Web
Below are the latest news stories about CHF Solutions Inc that investors may wish to consider to help them evaluate CHFS as an investment opportunity.
Registry will Support Real-World Efficacy of Fluid Management in ChildrenEDEN PRAIRIE, Minn., April 20, 2021 (GLOBE NEWSWIRE) -- More pediatric clinical evidence is essential in understanding the real-world benefits of medical devices in children. CHF Solutions is committed to expanding pediatric-specific data, and today announced Joe DiMaggio Children’s Hospital in Hollywood, Florida has enrolled the first patient in the Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds Registry). ULTRA-Peds will collect real-world evidence on the safety, performance and utilization of Aquadex SmartFlow® in fluid overloaded children who weigh 20 kg or more. CHF Solutions is the sponsor of the registry alongside collaborator Acute Kidney Injury Critical Care Research Foundation. Key clinical da...
The Portability of Aquadex SmartFlow® from CHF Solutions Could Mean More Critically-Ill Patients Have Access to Life-Saving Ultrafiltration Therapy
New Clinical Abstract Available Online During National Kidney Foundation Spring Clinical Meeting (NKF)EDEN PRAIRIE, Minn., April 08, 2021 (GLOBE NEWSWIRE) -- Bringing transportable care directly to patients who are too critically-ill to be moved could be the difference between life and death. New evidence demonstrates that ultrafiltration therapy (aquapheresis) using the Aquadex SmartFlow® system by CHF Solutions may be lifesaving for patients with profound and catastrophic multi-organ failure due to fluid overload, in part due to the device’s flexibility and portability. Aquadex™ gently removes excess fluid from the blood to alleviate burden on key organs such as the kidneys and heart. The case study, “Aquapheresis for Life-threatening Cardio-Respiratory Failure,” is part of an abstrac...
CHF Solutions, Inc. Announces Closing of $20.9 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option
EDEN PRAIRIE, Minn., March 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the closing of its previously announced underwritten public offering of 3,795,816 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $20.9 million, including the full exercise of the underwriters’ over-allotment option to purchase additional shares of the Company’s common stock, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Ladenburg Thalmann & Co. Inc. acted as sole book-running manager in connection with the offering. Lake Street Capital Markets, LLC acted as lead manager for the offering. Colliers Securities LLC and Maxim Group LLC acted as financial ...
EDEN PRAIRIE, Minn., March 17, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) today announced the pricing of an underwritten public offering of 3,300,710 shares of its common stock at a price to the public of $5.50 per share, for gross proceeds of approximately $18.1 million prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters an option, exercisable in whole or in part for 45 days, to purchase up to an additional 495,106 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the offering. Lake Street Capital Markets, LLC is acting a...
EDEN PRAIRIE, Minn., March 16, 2021 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) (the “Company”) announced today that it intends to offer shares of its common stock in an underwritten public offering. All of the shares of common stock to be sold in the offering will be offered by the Company. The Company intends to grant the underwriters a 45-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The Company intends to use the net proceeds for the offering for general corporate purposes, including the continued investment in commercialization efforts. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms ...
CHFS Price Returns